Innosuisse supports the Basel biotech company RocketVax in its research into the second generation of SARS-CoV-2 vaccines

When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working [...]

By |2021-04-19T13:39:52+01:0016th April, 2021|Press Release|

Prof. Dr. med. Alex A. Adjei, Chairman of the Oncology Advisory Committee of Swiss Rockets, is the 2020 Adi F. Gazdar IASLC Merit Award Recipient

Prof. Dr. Alex A. Adjei has been chosen as the inaugural recipient of the Adi F. Gazdar IASLC Merit Award. For his many accomplishments and a passion for cancer drug development, as well as for mentoring the next generation of specialists during his multifaceted career, Prof. Dr. Adjei has been selected for the award by [...]

By |2021-02-10T16:42:57+01:0010th February, 2021|Press Release|

Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

The rapid development of an effective and safe vaccine against SARS-CoV-2 is a top priority for Swiss Rockets AG. A Basel-based subsidiary, RocketVax AG, was founded to utilize innovative Swiss technologies and expertise to achieve this goal. "The development of a SARS-CoV-2 vaccine might be more complex than anticipated, and the first generation of vaccines [...]

By |2020-11-16T09:43:59+01:0010th November, 2020|Press Release|

The biotech company Swiss Rockets AG enters into a strategic partnership with daura AG – the Swiss platform for digital stocks

The collaboration between Swiss Rockets and daura is designed to facilitate the financing of promising life science projects. With the daura platform, investments in biotech start-ups will be possible digitally even with smaller amounts and without transaction costs. By selecting research projects in oncology and immunology, the biotech company Swiss Rockets supports a paradigm shift, [...]

By |2020-08-28T08:23:01+01:0027th August, 2020|Press Release|

Swiss Rockets AG has assembled an Advisory Committee of renowned Oncology scientists to help it develop new cancer treatments

Inspired by cancer patients and dedicated to their well-being, Swiss Rockets provides access to innovative anti-cancer treatments. Internationally recognized experts of the Oncology Advisory Committee accelerate and secure drug discovery programs as well as advise and lead clinical development of the most promising technologies.   Prof. Dr. med. Alex A. Adjei, Chairman of Oncology Advisory [...]

By |2020-06-09T08:28:22+01:005th June, 2020|Press Release|

Swiss Rockets AG: Scientific and Drug Discovery Advisory Committee opens a new chapter in cancer drug discovery and development

Swiss Rockets AG strives to provide cancer patients access to breakthrough innovative anti-cancer treatments. The highly experienced Scientific and Drug Discovery Advisory Committee of Swiss Rockets will provide expertise to guide the selection of the most promising technologies and their efficient pathway to market approval. Dr. Jeanette Wood, Chairman of Scientific and Drug Discovery [...]

By |2020-03-18T20:41:40+01:009th March, 2020|Press Release|

Swiss Rockets AG: Business Advisory Committee will combine business with the patients’ well-being

To deliver breakthrough treatments to cancer patients, Swiss Rockets supports innovation through investments in the novel and differentiated ideas and technologies. Swiss Rockets’ business model, promoted by highly competent members of the Business Advisory Committee, will ensure success in transforming cancer care with new and best in class medicines. Dr. Sabina R. Korfmann-Bodenmann, Chairman [...]

By |2020-03-18T21:05:22+01:0026th February, 2020|Press Release|

Prof. Dr. Michael N. Hall, member of the Board of Directors of Swiss Rockets AG, receives the Sjöberg Prize 2020

The Royal Swedish Academy of Sciences has awarded the Sjöberg Prize 2020 jointly to Prof. Michael N. Hall, Biozentrum of the University of Basel, and Prof. David M. Sabatini, Massachusetts Institute of Technology (MIT), Cambridge, USA. The two scientists receive this international award for their discovery of mTOR and its role in the control [...]

By |2021-02-10T15:02:32+01:0010th February, 2020|Press Release|

Swiss Rockets AG: The Executive Management Team – People make the Difference

Cancer patients of Swiss Rockets AG will benefit from new treatments developed using innovative and disruptive methods. The Swiss Rockets’ executive management team combines the necessary specialist knowledge and experience to efficiently and sustainably break new ground in cancer medicine. Swiss Rockets AG, Basel, founded in 2018, is implementing a paradigm shift in healthcare. [...]

By |2020-03-18T21:05:56+01:003rd February, 2020|Press Release|

Swiss Rockets implements a paradigm shift in the field of cancer research

The Swiss Rockets business model will bring advantages first and foremost to cancer patients, but also to researchers of new active substances, and investors. Forward-looking treatment methods within the therapeutic area of oncology will be identified, supported, and commercialized through the combining of services into an incubator for new oncology projects, through targeted investments [...]

By |2020-03-18T21:06:19+01:0026th November, 2019|Press Release|